Carl Stubbings

Carl is an experienced senior leader in the biotechnology and diagnostics industry with a focus on commercialisation, sales, marketing and business development.

He has considerable experience commercialising diagnostic products, both locally and globally. Based in the USA for 13 years, he served as Senior Vice President for Panbio USA Ltd and Vice-President of Sales and Marketing for Focus Diagnostics, a subsidiary of Quest Diagnostics (NASDAQ:DGX).

Since moving back to Australia Carl has held a number of executive roles including, Chief Business Officer at Benitec Biopharma Limited (ASX: BLT, NASDAQ: BNTC), CEO and Managing Director of Sienna Cancer Diagnostics Ltd (ASX: SDX), and Chief Operating Officer of BARD1(ASX:IIQ). More recently he was appointed Chief Commercial Officer of Genetic Technologies (ASX:GTG, NASDAQ :GENE). Carl has also assisted several Australian biotech companies with their commercialisation strategies, these companies include BCAL Diagnostics (ASX:BDX), Biotron (ASX: BIT) and Minomic International. He is also a Non-Executive Director of Sangui Bio, an unlisted private company. 

Carl has Bachelor of Applied Science (Medical Technology) from Queensland University of Technology.